10.09.15
UK-based ADC Biotechnology has announced a $10 million plan to build a 1,500 square-meter manufacturing facility for advanced anti-cancer drugs.
The two-stage expansion program marks the transition of ADC BIO into GMP manufacturing of ADCs ( Antibody drug conjugates) and will create over 60 new science jobs at completion.
The investment responds to demand by drug developers and a shortage of capacity to make these new drugs in quantities sufficient for large-scale Clinical Trials .
Phase 1 of the project will come on stream in mid-2017, creating a 1,500 square-meter state-of-the-art, dual-stream facility for process development, manufacturing and quality testing of ADC drugs.
From both scale and regulatory perspectives, the new facility will be able to produce clinical trial and low-volume commercial quantities. Production will be in cutting edge Cleanroom facilities, accommodating both ADC Bio’s proprietary Lock-Release technology and conventional, Solution -phase production.
The facility will bring process development, manufacture, quality control, quality assurance and Stability testing together under one roof at ADC Bio’s operational headquarters in St. Asaph, North Wales.
A projected second phase is planned to add another 2,500 square-meters of manufacturing space for larger scale clinical and commercial manufacturing.
The two-stage expansion program marks the transition of ADC BIO into GMP manufacturing of ADCs ( Antibody drug conjugates) and will create over 60 new science jobs at completion.
The investment responds to demand by drug developers and a shortage of capacity to make these new drugs in quantities sufficient for large-scale Clinical Trials .
Phase 1 of the project will come on stream in mid-2017, creating a 1,500 square-meter state-of-the-art, dual-stream facility for process development, manufacturing and quality testing of ADC drugs.
From both scale and regulatory perspectives, the new facility will be able to produce clinical trial and low-volume commercial quantities. Production will be in cutting edge Cleanroom facilities, accommodating both ADC Bio’s proprietary Lock-Release technology and conventional, Solution -phase production.
The facility will bring process development, manufacture, quality control, quality assurance and Stability testing together under one roof at ADC Bio’s operational headquarters in St. Asaph, North Wales.
A projected second phase is planned to add another 2,500 square-meters of manufacturing space for larger scale clinical and commercial manufacturing.
